NASDAQ
163.05USD
+2.38 (+1.48%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.5B
P/E
—
EPS
—
Beta
-1.23
52W range
60-200
Day range
161.67–164.20
Open
161.67
Prev close
160.67
Volume
126.4K
Avg volume
159.8K
Dividend
0.00
IPO
2022-04-29
https://www.marketbeat.com/instant-alerts/belite-bio-eyes-priority-fda-review-as-tinlarebant-targets-stargardt-disease-2026-07-09/ · 7/10/2026+0.80
https://www.globenewswire.com/news-release/2026/06/13/3311366/0/en/Belite-Bio-Completes-Rolling-Submission-of-New-Drug-Application-to-U-S-Food-and-Drug-Administration-for-Tinlarebant-for-the-Treatment-of-Stargardt-Disease-Type-1.html · 6/13/2026+1.00
https://seekingalpha.com/article/4913057-belite-bio-inc-blte-presents-at-goldman-sachs-47th-annual-global-healthcare-conference-2026 · 6/8/2026+0.20
https://seekingalpha.com/article/4904329-belite-bio-inc-blte-presents-at-bank-of-america-global-healthcare-conference-2026-transcript · 5/14/2026+0.00
https://www.globenewswire.com/news-release/2025/11/02/3178795/0/en/Belite-Bio-Announces-UK-s-Medicines-and-Healthcare-Products-Regulatory-Agency-Agrees-to-Conditional-Marketing-Authorization-Application-Based-on-Interim-Analysis-Results-for-the-Tr.html · 11/2/2025+0.80
https://seekingalpha.com/article/4812439-belite-bio-inc-blte-q2-2025-earnings-call-transcript · 8/12/2025+0.00
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
